Recent insights into the mechanism and consequences of TRIM5α retroviral restriction

AIDS Research and Human Retroviruses

Volumn 27, Issue 3, 2011, Pages 231-238

  Sastri, Jaya ^a   Campbell, Edward M ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN A; GELDANAMYCIN; GLUTARALDEHYDE; PROTEASOME; RIBONUCLEOPROTEIN; TRIPARTITE MOTIF PROTEIN 5;

CARBOXY TERMINAL SEQUENCE; CELL DESTRUCTION; CYTOPLASM; DIMERIZATION; DISEASE COURSE; DNA POLYMORPHISM; GENE FREQUENCY; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PATHOGENESIS; POPULATION; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN MULTIMERIZATION; REVERSE TRANSCRIPTION; REVIEW; RHESUS MONKEY; SINGLE NUCLEOTIDE POLYMORPHISM; VIRION; VIRUS CAPSID; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; CAPSID; CARRIER PROTEINS; HIV-1; HUMANS; LEUKEMIA VIRUS, MURINE; POLYMORPHISM, GENETIC; RETROVIRIDAE;

EID: 79952582574     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0367     Document Type: Review

References (82)

1. Bieniasz PD: Intrinsic immunity: A front-line defense against viral attack. Nat Immunol 2004;5:1109-1115. (Pubitemid 39549624)
2. Goff SP: Retrovirus restriction factors. Mol Cell 2004;16: 849-859. (Pubitemid 40018396)
3. Stremlau M, et al.: The cytoplasmic body component TRI-M5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004;427:848-853. (Pubitemid 38297747)
4. Sayah DM, et al.: Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 2004;430:569-573. (Pubitemid 38998631)
5. Keckesova Z, et al.: The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restric-tion factor activities. Proc Natl Acad Sci USA 2004;101: 10780-10785. (Pubitemid 38955819)
6. Perez-Caballero D, et al.: Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J Virol 2005;79:8969-8978. (Pubitemid 40934808)
7. Song B, et al.: Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. J Virol 2005;79: 3930-3937. (Pubitemid 40388333)
8. Pacheco B, et al.: Species-specific inhibition of foamy viruses from South American monkeys by New World Monkey TRIM5{alpha} proteins. J Virol 2010;84:4095-4099.
9. Brennan G, et al.: TRIMCyp expression in Old World pri-mates Macaca nemestrina and Macaca fascicularis. Proc Natl Acad Sci USA 2008;105:3569-3574. (Pubitemid 351723593)
10. Carthagena L, et al.: Implication of TRIM alpha and TRIM-Cyp in interferon-induced anti-retroviral restriction activi-ties. Retrovirology 2008;5:59.
11. Diaz-Griffero F, et al.: Requirements for capsid-binding and an effector function in TRIMCyp-mediated restriction of HIV-1. Virology 2006;351:404-419. (Pubitemid 44131556)
12. Liao CH, et al.: A novel fusion gene, TRIM5-cyclophilin A in the pig-tailed macaque determines its susceptibility to HIV-1 infection. AIDS 2007;21(Suppl 8):S19-S26.
13. Newman RM, et al.: Evolution of a TRIM5-CypA splice isoform in Old World monkeys. PLoS Pathog 2008;4: e1000003.
14. Nisole S, et al.: A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc Natl Acad Sci USA 2004;101:13324-13328. (Pubitemid 39209664)
15. Si Z, et al.: Evolution of a cytoplasmic tripartite motif (TRIM) protein in cows that restricts retroviral infection. Proc Natl Acad Sci USA 2006;103:7454-7459. (Pubitemid 43727854)
16. Ylinen LM, et al.: Isolation of an active Lv1 gene from cattle indicates that tripartite motif protein-mediated innate im-munity to retroviral infection is widespread among mam-mals. J Virol 2006;80:7332-7338. (Pubitemid 44092556)
17. Fletcher AJ, et al.: Hare TRIM5alpha restricts divergent ret-roviruses and exhibits significant sequence variation from closely related lagomorpha TRIM5 genes. J Virol 2010;84: 12463-12468.
18. Schaller T, et al.: An active TRIM5 protein in rabbits indicates a common antiviral ancestor for mammalian TRIM5 pro-teins. J Virol 2007;81:11713-11721. (Pubitemid 47623803)
19. Sawyer SL, et al.: Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction do-main. Proc Natl Acad Sci USA 2005;102:2832-2837. (Pubitemid 40299877)
20. Song B, et al.: The B30.2(SPRY) domain of the retroviral re-striction factor TRIM5alpha exhibits lineage-specific length and sequence variation in primates. J Virol 2005;79:6111-6121. (Pubitemid 40617216)
21. Nisole S, et al.: TRIM family proteins: Retroviral restriction and antiviral defence. Nat Rev Microbiol 2005;3:799-808. (Pubitemid 41518740)
22. Reymond A, et al.: The tripartite motif family identifies cell compartments. EMBO J 2001;20:2140-2151. (Pubitemid 32410584)
23. Yamauchi K, et al.: Ubiquitination of E3 ubiquitin ligase TRIM5 alpha and its potential role. FEBS J 2008;275:1540-1555. (Pubitemid 351388800)
24. Diaz-Griffero F, et al.: A B-box 2 surface patch important for TRIM5alpha self-association, capsid binding avidity, and retrovirus restriction. J Virol 2009;83:10737-10751.
25. Perez-Caballero D, et al.: Restriction of human immunode-ficiency virus type 1 by TRIM-CypA occurs with rapid ki-netics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J Virol 2005;79:15567-15572. (Pubitemid 43032338)
26. Song B, et al.: TRIM5alpha association with cytoplasmic bodies is not required for antiretroviral activity. Virology 2005;343:201-211. (Pubitemid 41598361)
27. Campbell EM, et al.: Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha. J Cell Biol 2008;180:549-561. (Pubitemid 351240703)
28. Sastri J, et al.: Identification of residues within the L2 region of TRIM5α that are required for retroviral restriction and cytoplasmic body localization. Virology 2010;405:259-266.
29. Javanbakht H, et al.: Characterization of TRIM5alpha tri-merization and its contribution to human immunodeficiency virus capsid binding. Virology 2006;353:234-246. (Pubitemid 44308489)
30. Mische CC, et al.: Retroviral restriction factor TRIM5alpha is a trimer. J Virol 2005;79:14446-14450. (Pubitemid 41552743)
31. Kar AK, et al.: Biochemical and biophysical characterization of a chimeric TRIM21-TRIM5alpha protein. J Virol 2008;82: 11669-11681.
32. Langelier CR, et al.: Biochemical characterization of a re-combinant TRIM5alpha protein that restricts human im-munodeficiency virus type 1 replication. J Virol 2008;82: 11682-11694.
33. Javanbakht H, et al.: The ability of multimerized cyclophilin A to restrict retrovirus infection. Virology 2007;367:19-29. (Pubitemid 47432785)
34. Javanbakht H, et al.: The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRI-M5alpha. J Biol Chem 2005;280:26933-26940. (Pubitemid 41040729)
35. Nepveu-Traversy ME, et al.: TRIM5alpha and TRIMCyp form apparent hexamers and their multimeric state is not affected by exposure to restriction-sensitive viruses or by treatment with pharmacological inhibitors. Retrovirology 2009;6:100.
36. Li X and Sodroski J: The TRIM5alpha B-box 2 domain promotes cooperative binding to the retroviral capsid by mediating higher-order self-association. J Virol 2008;82:11495-11502.
37. Li X, et al.: Functional interplay between the B-box 2 and the B30.2(SPRY) domains of TRIM5alpha. Virology 2007;366: 234-244. (Pubitemid 47398911)
38. Ganser-Pornillos BK, et al.: Hexagonal assembly of a re-stricting TRIM5{alpha} protein. Proc Natl Acad Sci USA 2011;108:534-539.
39. Stremlau M, et al.: Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J Virol 2005; 79:3139-3145. (Pubitemid 40270592)
40. Ohkura S, et al.: All three variable regions of the TRIM5alpha B30.2 domain can contribute to the specificity of retrovirus restriction. J Virol 2006;80:8554-8565. (Pubitemid 44384867)
41. Yap MW, et al.: A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol 2005;5:3-8.
42. Virgen CA, et al.: Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. Proc Natl Acad Sci USA 2008;105:3563-3568. (Pubitemid 351723592)
43. Wilson SJ, et al.: Independent evolution of an antiviral TRIMCyp in rhesus macaques. Proc Natl Acad Sci USA 2008;105:3557-3562. (Pubitemid 351723591)
44. Colgan J, et al.: Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization. J Virol 1996;70:4299-4310. (Pubitemid 26187431)
45. Franke EK, et al.: Specific incorporation of cyclophilin A into HIV-1 virions. Nature 1994;372:359-362. (Pubitemid 24363437)
46. Forshey BM, et al.: Structural requirements for recognition of the human immunodeficiency virus type 1 core during host restriction in owl monkey cells. J Virol 2005;79:869-875. (Pubitemid 40053870)
47. Sebastian S and Luban J: TRIM5alpha selectively binds a re-striction-sensitive retroviral capsid. Retrovirology 2005;2:40.
48. Stremlau M, et al.: Specific recognition and accelerated un-coating of retroviral capsids by the TRIM5{alpha} restriction factor. Proc Natl Acad Sci USA 2006;103:5514-5519.
49. Johnson WE and Sawyer SL: Molecular evolution of the an-tiretroviral TRIM5 gene. Immunogenetics 2009;61:163-176.
50. Ortiz M, et al.: Evolutionary trajectories of primate genes in-volved in HIV pathogenesis. Mol Biol Evol 2009;26:2865-2875.
51. Maillard PV, et al.: The specificity of TRIM5 alpha-mediated restriction is influenced by its coiled-coil domain. J Virol 2010;84:5790-5801.
52. Campbell EM, et al.: TRIM5 alpha cytoplasmic bodies are highly dynamic structures. Mol Biol Cell 2007;18:2102-2111. (Pubitemid 46911362)
53. Dvorin JD and Malim MH: Intracellular trafficking of HIV-1 cores: Journey to the center of the cell. Curr Top Microbiol Immunol 2003;281:179-208. (Pubitemid 36950686)
54. Perron MJ, et al.: TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc Natl Acad Sci USA 2004;101:11827-11832. (Pubitemid 39095379)
55. Diaz-Griffero F, et al.: Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp. J Virol 2007;8:32.
56. Diaz-Griffero F, et al.: Modulation of retroviral restriction and proteasome inhibitor-resistant turnover by changes in the TRIM5{alpha} B-box 2 Domain. J Virol 2007;81:10362-10378. (Pubitemid 47463311)
57. Chatterji U, et al.: Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry. J Biol Chem 2006;281:37025-37033. (Pubitemid 46042173)
58. Anderson JL, et al.: Proteasome inhibition reveals that a functional preintegration complex intermediate can be gen-erated during restriction by diverse TRIM5 proteins. J Virol 2006;80:9754-9760. (Pubitemid 44435649)
59. Wu X, et al.: Proteasome inhibitors uncouple rhesus TRI-M5alpha restriction of HIV-1 reverse transcription and in-fection. Proc Natl Acad Sci USA 2006;103:7465-7470. (Pubitemid 43727856)
60. Rold CJ and Aiken C: Proteasomal degradation of TRI-M5alpha during retrovirus restriction. PLoS Pathog 2008; 4:e1000074.
61. O'Connor C, et al.: p62/sequestosome1 associates with and sustains the expression of the retroviral restriction factor TRIM5{alpha}. J Virol 2010;84:5997-6006.
62. Kim JY and Ozato K: The sequestosome 1/p62 attenuates cytokine gene expression in activated macrophages by in-hibiting IFN regulatory factor 8 and TNF receptor-associated factor 6/NF-kappaB activity. J Immunol 2009;182:2131-2140.
63. Moscat J, et al.: Signal integration and diversification through the p62 scaffold protein. Trends Biochem Sci 2007; 32:95-100. (Pubitemid 46199192)
64. Seibenhener ML, et al.: Sequestosome 1/p62 is a poly-ubiquitin chain binding protein involved in ubiquitin pro-teasome degradation. Mol Cell Biol 2004;24:8055-8068. (Pubitemid 39167456)
65. Hwang CY, et al.: Hsp70 interacts with the retroviral re-striction factor TRIM5alpha and assists the folding of TRI-M5alpha. J Biol Chem 2010;285:7827-7837
66. Wooten MW, et al.: Essential role of sequestosome 1/p62 in regulating accumulation of Lys63-ubiquitinated proteins. J Biol Chem 2008;283:6783-6789.
67. Kim PK, et al.: Ubiquitin signals autophagic degradation of cytosolic proteins and peroxisomes. Proc Natl Acad Sci USA 2008;105:20567-20574.
68. Komatsu M, et al.: The selective autophagy substrate p62 ac-tivates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 2010;12:213-223.
69. Pankiv S, et al.: p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 2007;282:24131-24145. (Pubitemid 47328003)
70. Sawyer SL, et al.: High-frequency persistence of an impaired allele of the retroviral defense gene TRIM5alpha in humans. Curr Biol 2006;16:95-100. (Pubitemid 43049892)
71. Javanbakht H, et al.: Effects of human TRIM5alpha polymor-phisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology 2006;354:15-27 (Pubitemid 44468115)
72. Goldschmidt V, et al.: Role of common human TRIM5alpha variants in HIV-1 disease progression. Retrovirology 2006;3:54.
73. van Manen D, et al.: The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog 2008; 4:e18.
74. Speelmon EC, et al.: Genetic association of the antiviral re-striction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J Virol 2006;80:2463-2471. (Pubitemid 43271552)
75. Kirmaier A, et al.: TRIM5 suppresses cross-species trans-mission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol 2010;8.
76. Lim SY, et al.: TRIM5alpha modulates immunodeficiency virus control in rhesus monkeys. PLoS Pathog 2010;6:e1000738.
77. Newman RM, et al.: Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5al-pha. Proc Natl Acad Sci USA 2006;103:19134-19139. (Pubitemid 350010634)
78. Wilson SJ, et al.: Rhesus macaque TRIM5 alleles have di-vergent antiretroviral specificities. J Virol 2008;82:7243-7247. (Pubitemid 351977742)
79. Ourmanov I, et al.: Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunode-ficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques. J Virol 2000;74:2960-2965. (Pubitemid 30117614)
80. Polacino P, et al.: Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. J Virol 1999;73:618-630. (Pubitemid 28565406)
81. Yasutomi Y, et al.: Simian immunodeficiency virus-specific CD8 + lymphocyte response in acutely infected rhesus monkeys. J Virol 1993;67;1707-1711. (Pubitemid 23067685)
82. Hirsch V, et al.: A molecularly cloned, pathogenic, neutralization- resistant simian immunodeficiency virus, SIVsmE543-3. J Virol 1997;71:1608-1620. (Pubitemid 27030338)